Gastric Cancer Classification Isn't As Simple As You Think
Gastric cancer classification refers to the systematic categorization of stomach cancers based on their histological appearance, anatomical location, molecular features, and clinical behavior, enabling clinicians to guide diagnosis, treatment, and prognosis. The most widely used systems include the Lauren classification, WHO histological classification, and TNM staging system, each offering distinct insights into tumor biology and progression.
Core classification systems
The field of gastric cancer classification has evolved significantly since the mid-20th century, when Finnish pathologist Pekka Lauren introduced his now-classic framework in 1965. Today, clinicians combine multiple classification models to improve treatment accuracy and survival outcomes, particularly as gastric cancer remains the fifth most common cancer globally, with approximately 1.1 million new cases reported annually as of 2024.
- Lauren classification: Divides tumors into intestinal and diffuse types based on histology.
- WHO classification: Focuses on microscopic tumor morphology and cellular differentiation.
- TNM staging system: Evaluates tumor spread using Tumor size, Node involvement, and Metastasis.
- Molecular classification: Uses genetic and biomarker data, including HER2 and MSI status.
Lauren classification explained
The Lauren classification system remains one of the most clinically relevant frameworks due to its simplicity and prognostic value. It divides gastric cancers into two primary types, each associated with distinct epidemiological patterns and outcomes.
- Intestinal type: Often linked to environmental factors such as diet and Helicobacter pylori infection; tends to form gland-like structures and is more common in older patients.
- Diffuse type: Characterized by poorly cohesive cells, including signet ring cells; more aggressive and often affects younger individuals.
Studies published in The Lancet Oncology in 2023 indicated that patients with intestinal-type tumors have a 5-year survival rate of approximately 45%, compared to just 25% for diffuse-type tumors, highlighting the clinical importance of this histological classification.
WHO histological classification
The WHO classification system, updated in 2019, provides a more granular breakdown of gastric cancers based on microscopic cellular features. It is widely used by pathologists to guide diagnosis and research.
| Subtype | Description | Prevalence (%) |
|---|---|---|
| Adenocarcinoma | Most common type, arising from glandular cells | 90% |
| Signet ring cell carcinoma | Cells contain mucin pushing nucleus to the edge | 10-20% |
| Mucinous adenocarcinoma | Produces large amounts of extracellular mucin | 5-10% |
| Poorly cohesive carcinoma | Cells lack adhesion, leading to diffuse spread | 15% |
This microscopic tumor classification allows clinicians to identify aggressive variants early and tailor treatment protocols accordingly.
TNM staging system
The TNM staging system, developed by the American Joint Committee on Cancer (AJCC), is essential for determining disease progression and guiding treatment decisions. It is updated periodically, with the latest 8th edition released in 2017 and still widely used in 2026.
- T (Tumor): Measures how deeply the tumor has invaded the stomach wall layers.
- N (Nodes): Assesses the number of nearby lymph nodes involved.
- M (Metastasis): Indicates whether the cancer has spread to distant organs.
For example, a tumor classified as T3N2M0 indicates deep invasion into the stomach wall, involvement of several lymph nodes, but no distant metastasis. This clinical staging framework is critical for determining whether surgery, chemotherapy, or palliative care is appropriate.
Molecular classification advances
The molecular classification of gastric cancer represents a major breakthrough in oncology, driven by genomic research such as The Cancer Genome Atlas (TCGA) project published in 2014. This approach categorizes tumors based on genetic alterations rather than just morphology.
- EBV-positive tumors: Associated with Epstein-Barr virus infection and better prognosis.
- Microsatellite instability (MSI): High mutation rates, often responsive to immunotherapy.
- Genomically stable tumors: Frequently correspond to diffuse-type cancers.
- Chromosomal instability (CIN): Characterized by gene amplifications, including HER2.
According to a 2025 report from the European Society for Medical Oncology, patients with MSI-high tumors showed a 60% response rate to checkpoint inhibitors, demonstrating the clinical impact of precision oncology classification.
Clinical relevance and treatment impact
The integration of gastric cancer classification systems directly influences treatment strategies and patient outcomes. For instance, HER2-positive tumors may benefit from targeted therapies such as trastuzumab, while MSI-high cancers are often treated with immunotherapy agents like pembrolizumab.
Surgeons and oncologists rely on combined classification data to determine whether a patient is eligible for curative gastrectomy, neoadjuvant chemotherapy, or experimental therapies in clinical trials. A 2024 multicenter study across Europe found that personalized treatment based on combined classification improved survival rates by 18% compared to standard approaches.
Historical evolution
The history of gastric cancer classification reflects broader advances in medical science. Early classifications in the 19th century were purely descriptive, focusing on tumor appearance during autopsy. The introduction of microscopy in the early 20th century enabled histological categorization, culminating in Lauren's system in 1965.
"The classification of tumors is not merely academic-it is the foundation of rational therapy," noted Dr. Pekka Lauren in his original 1965 publication.
In the 21st century, genomic sequencing has transformed classification into a dynamic, data-driven process, allowing clinicians to move beyond morphology toward molecularly guided treatment.
Practical example
A patient diagnosed with gastric cancer in Amsterdam in 2025 underwent comprehensive classification: histology revealed diffuse-type carcinoma, TNM staging was T4N1M0, and molecular testing showed genomic stability without HER2 amplification. This integrated diagnostic approach led clinicians to prioritize chemotherapy over targeted therapy, illustrating how classification directly shapes care decisions.
FAQs
Everything you need to know about Gastric Cancer Classification Isnt As Simple As You Think
What is the most common classification system for gastric cancer?
The Lauren classification is one of the most widely used systems, dividing gastric cancer into intestinal and diffuse types based on histological features, due to its simplicity and strong prognostic value.
Why is TNM staging important in gastric cancer?
TNM staging is crucial because it determines how far the cancer has spread, guiding treatment decisions such as surgery, chemotherapy, or palliative care, and helping predict patient outcomes.
What role does molecular classification play?
Molecular classification identifies genetic and biomarker differences in tumors, enabling personalized treatments such as immunotherapy or targeted therapy, significantly improving response rates in certain patients.
How does diffuse-type gastric cancer differ from intestinal type?
Diffuse-type gastric cancer is more aggressive, lacks gland formation, and often affects younger patients, while intestinal type is typically linked to environmental factors and has a better prognosis.
Can gastric cancer classification change over time?
Yes, as new diagnostic tools and genetic insights emerge, classification systems are updated to reflect improved understanding of tumor biology and treatment response.